logo-loader
AIM:SCLP OTC:SCNLF

Scancell Holdings PLC

Receive alerts
Market:
AIM
Price
79.58 GBX
Day Change
0.73%
Market Cap:
£107.96 m
52 weeks high
295.00
52 weeks low
78.00

In brief

Scancell is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody® and Moditope® platforms, designed to stimulate durable anti-tumor responses.

The lead product, iSCIB1+, is a DNA ImmunoBody® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma.

Snapshot

  • Scancell's melanoma vaccine wins FDA designation as phase III trial nears
  • Scancell's latest deal is only part of the story for this ambitious cancer vaccine specialist
  • Cancer vaccine breakthrough at Moderna raises hopes for Scancell's melanoma programme
  • Scancell CSO Professor Lindy Durrant hails positive melanoma data